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Aim: Arteriovenous fistula-formation remains critical for the provision of hemodialysis in end-
stage renal failure patients. Its creation results in a significant increase in cardiac output, with 
resultant alterations in cardiac stroke volume, systemic blood flow, and vascular resistance. The 
impact of fistula-formation on cardiac and vascular structure and function has not yet been evalu-
ated via “gold standard” imaging techniques in the modern era of end-stage renal failure care.
Methods: A total of 24 patients with stage 5 chronic kidney disease undergoing fistula-creation 
were studied in a single-arm pilot study. Cardiovascular magnetic resonance imaging was 
undertaken at baseline, and prior to and 6 months following fistula-creation. This gold standard 
imaging modality was used to evaluate, via standard brachial flow-mediated techniques, cardiac 
structure and function, aortic distensibility, and endothelial function.
Results: At follow up, left ventricular ejection fraction remained unchanged, while mean cardiac 
output increased by 25.0% (P,0.0001). Significant increases in left and right ventricular end-
systolic volumes (21% [P=0.014] and 18% [P,0.01]), left and right atrial area (11% [P,0.01] 
and 9% [P,0.01]), and left ventricular mass were observed (12.7% increase) (P,0.01). 
Endothelial-dependent vasodilation was significantly decreased at follow up (9.0%±9% vs 
3.0%±6%) (P=0.01). No significant change in aortic distensibility was identified.
Conclusion: In patients with end-stage renal failure, fistula-formation is associated with an 
increase in cardiac output, dilation of all cardiac chambers and deterioration in endothelial 
function.
Keywords: cardiac, cardiovascular disease, vascular biology
Introduction
Hemodialysis (HDx) remains the cornerstone of renal replacement therapy for  end-stage 
renal failure (ESRF) patients worldwide. However its creation has a number of adverse 
hemodynamic consequences. Immediately following creation, arteriovenous fistula 
(AVF) is associated with an increase in cardiac output (CO), achieved  predominantly 
through a reduction in systemic vascular resistance, increased myocardial  contractility, 
and an increase in stroke volume (SV) and heart rate.1 Over the following week, 
circulating blood volume increases in conjunction with increases in atrial and brain 
natriuretic peptides.2,3 These alterations are associated with early increases in left 
ventricular (LV) filling pressure with the potential for resultant impact on atrial and 
ventricular chamber dimensions and function.2
To maintain sufficient systemic perfusion, CO must increase proportionately, 
resulting in longer-term implications for cardiac and vascular structure and function.3–5 
Historically, AVF-creation has been associated with worsening of LV hypertrophy and 





resultant diastolic dysfunction and left atrial dilatation.2,6 
In some patients, a giant AVF may lead to progressive 
high-output cardiac failure, despite preserved LV systolic 
function.7–9 To date, many of the studies evaluating the 
cardiovascular (CV) effects of AVF have used an echocar-
diographic methodology.
CV magnetic resonance (CMR) imaging has been 
recognized as the modern “gold standard” for the evalua-
tion of cardiac structure and function. Assessing, not only 
cardiac, but also, vascular structure and function, CMR has 
substantially greater accuracy and reproducibility for the 
assessment of cardiac indices compared with alternative 
methodologies, such as echocardiography.10–16 Importantly, 
CMR can assess aortic stiffness, which has proven prog-
nostic significance in patients with chronic kidney disease 
(CKD).14,17,18 Furthermore, this imaging modality can assess 
peripheral arterial diameter and flow – allowing the serial 
evaluation of alterations in brachial artery flow induced by 
distal AVF-formation, as well as evaluation of peripheral 
artery endothelial function – by a standard flow-mediated 
dilatation technique. Thus, CMR is able to provide accurate, 
reproducible, and comprehensive assessments of cardiac and 
vascular structure and function within a single investigation 
but has not been previously utilized for evaluating the impact 
of AVF-creation on cardiac and vascular function.
This study sought to evaluate the effects of AVF-creation 
on CV structure and function in the modern era of ESRF 
management, utilizing recent advances in noninvasive CMR 
imaging.
Methods
This study was approved by the Ethics of Human Research 
Committee of the Royal Adelaide Hospital. Written informed 
consent was obtained from all patients prior to study entry.
Patients aged .18 years with advanced stage 5 CKD were 
recruited prior to clinically driven, elective AVF-creation 
for anticipated HDx commencement in the subsequent 
6–12months. Patients with previous AVF-creation, renal 
replacement therapy, or deteriorating renal dysfunction 
anticipated to require HDx within the following 6 months 
were excluded. Patients with significant preexisting valvular 
heart disease or contraindications to magnetic resonance 
imaging were also excluded.
study investigations
Following informed consent, all subjects were scheduled 
for elective surgical AVF-formation, as per institutional 
 clinical practice. Clinical history and study CMR  evaluation 
of baseline CV structure and function were scheduled 
to occur 2 weeks prior to the elective surgical date. At 
6 months  following elective AVF-formation, repeat clinical 
history and the identical CMR protocol were performed, to 
evaluate alterations in CV structure and function following 
AVF-formation and maturation in the context of declining 
renal function.
cMR protocol
All CMR studies were performed utilizing a Siemens 
 Magnetom® Avanto 1.5 Tesla magnetic resonance imaging 
scanner (Siemens AG, Erlangen, Germany).
cardiac protocol
Cardiac structure and function studies were undertaken 
as previously described.19–21 In summary, retrospectively 
electrocardiogram (ECG)-gated true fast imaging with 
steady-state free precession (TrueFISP) CMR sequences 
were performed during expiratory breath holding, to assess 
atrial area and ventricular structure and function (25 phases 
per cardiac cycle; TR 2.7 ms, TE 1.4 ms, flip angle 60°). 
Long-axis reference views were used for positioning 8–12 
perpendicular LV short-axis slices from the level of the mitral 
valve to the LV apex. The short axis section thickness was 
6 mm, with short-axis intersection intervals of 4 mm.
Offline analysis was performed to determine diastolic and 
systolic cardiac chamber dimensions and diastolic LV mass, 
utilizing proprietary software (Argus Software, Houston, TX, 
USA) and standard methodology.19,20 For the right ventricular 
(RV) and LV data set, short-axis endocardial and epicardial 
contours were manually traced in end diastole (start of the 
R wave) and end systole. The LV and RV end-diastolic and 
end-systolic cavity surface areas were summed to obtain 
volumes, with a standard Simpson’s rule used to evaluate the 
ejection fraction, as previously described.21 The LV and RV 
end-diastolic volumes, end-systolic volumes, SVs, ejection 
fractions, CO, and LV mass, indexed to body surface area, 
were thus derived via standard equations. Minimal intra- and 
interobserver variability exists in these chamber measure-
ments, as previously published by our group.21
Vascular protocol
aortic distensibility
Immediately following completion of the cardiac protocol, 
ECG-gated TrueFISP cine sequences were acquired of 
the ascending aorta (AA), descending thoracic aorta, and 
proximal abdominal aorta, in a sagittal oblique orienta-
tion. Utilizing the midpoint of the right pulmonary artery 




Cardiovascular adaptations to AV fistula-creation
as the reference level in each patient, a perpendicular 
cross-sectional TrueFISP cine image was then taken at the 
AA and the proximal descending aorta (PDA). A final True-
FISP cine image was then acquired at the level of the distal 
descending aorta (DDA), 5–10 cm distal to the diaphragm, 
as previously described.15
Brachial artery blood pressure was taken concurrently, 
using a magnetic resonance imaging–compatible automated 
noninvasive sphygmomanometer, with the results of three 
measurements averaged.











Measures of aortic distensibility were recorded at each 
location individually, and then the three measurements 
were averaged, for an indicative average aortic distensi-
bility for each subject. Minimal intra- and interindividual 
 variability exists in our laboratory for this measurement 
(1% and 2% respectively).15
Brachial artery blood flow – AVF arm
Brachial artery blood flow was then quantified in the AVF 
arm, utilizing a dedicated velocity-encoded sequence opti-
mized for peak brachial artery flow velocity. Analysis of 
brachial artery flow was performed offline, utilizing propri-
etary software (Argus Software), at baseline and 6 months 
following AVF surgery.
Brachial artery flow-mediated dilatation
Brachial artery cross-sectional area and blood flow was then 
measured in the arm contralateral to the AVF. Utilizing 
validated techniques, endothelium-dependent endothelial 
function was assessed using a brachial artery flow-mediated 
vasodilation technique.22–24 Following a 10-minute period of 
rest, endothelium-independent function was assessed at the 
identical arterial location, following response to sublingual 
glyceryl trinitrate,24 and images analyzed offline.
statistical methods
All measures were tested for normality using the 
 Kolmogorov–Smirnov/Lilliefors Test. All normally distrib-
uted values were represented as mean ± standard deviation. 
Parameters that were deemed nonparametrically distributed 
were reported as median and interquartile range (IQR). Paired 
parameters were analyzed by two-tailed paired Student’s t-test. 
Where normally distributed, comparison of nonpaired measures 
was performed by unpaired t-test or one-way analysis of vari-
ance (ANOVA), as appropriate. Where parameters were not nor-
mally distributed, paired analyses were performed  utilizing the 
Wilcoxon matched pairs test, and nonpaired analyses were per-
formed using the Mann–Whitney U test.  Correlation between 
parameters was performed, using a Pearson’s  correlation for 
normally distributed samples, and Spearman’s correlation 
for nonparametric data. Comparison of binary test outcomes 
pre- and postsurgery was performed using Fisher’s exact test. 
Significance was predetermined as P,0.05.
Results
A total of 24 patients were evaluated at baseline and 6 months 
following successful AVF-creation (age 59±12 years, 
58% male) (Table 1). The average time from surgery to 
follow-up scan was 198±32 days. No patients had com-
menced HDx at the time of follow up.
Clinical and serological indices at 6 months were pre-
dominantly unchanged following AVF-creation (weight 
80±19 kg vs 78±17 kg) [P=0.07]; systolic blood pres-
sure 146±19 mmHg vs 146±17 mmHg [P=0.96]; Hb 
115±12 g/dL vs 119±15 g/dL [P=0.26]). All subjects were 
undergoing treatment with erythropoietin (EPO)-analogues 
at baseline and at follow up. Notably, resting heart rate was 
significantly increased at follow up compared with baseline 
(71±12 bpm vs 76±11 bpm [P=0.008]). Serum creatinine 
increased  significantly 6 months following study enrol-
ment, as would be expected clinically (529±91 µmol/L vs 
652±123 µmol/L [P=0.0006]).
cardiac results
In the presence of advanced CKD, baseline imaging in our 
cohort revealed some interesting observations compared 
Table 1 subject baseline characteristics
Characteristic N=24
age (years) 59±12
sex (male), % (n) 58 (14)
hypertension, % (n) 88 (21)
hyperlipidemia, % (n) 54 (13)
Type 2 diabetes mellitus, % (n) 38 (9)








Prior coronary artery disease, % (n) 21 (5)
cerebrovascular disease, % (n) 8 (2)
chronic pulmonary disease, % (n) 21 (5)
Baseline creatinine (µmol/l) 552±130





with previously published controls.25,26 Preserved LV  systolic 
function (LV ejection fraction [LVEF] 72%±7%), with 
normal LV end-diastolic volumes (149±31 mL) and CO 
(7.5±1.5 L/min), was observed. Despite the high prevalence 
of hypertension, LV mass was within normal limits at  baseline 
(132±33 g). The left atrial area was mildly increased across 
the cohort at baseline (27±6 cm2), with the right atrial area 
at the upper limits of the normal range (23±6 cm2).
Substantial alterations in cardiac structure and function 
were identified at follow up, as shown in Table 2 and both 
Figures 1 and 2.
Notably, 62.5% of subjects had CMR measures for LVEF, 
LV end-diastolic volume, LV end-systolic volume, LVSV, 
and LV mass index within normal limits prior to AVF-
creation; however, this had reduced to 41.7% of subjects, at 
6 months following AVF-creation (P=0.24).
Vascular results
aortic distensibility
Aortic distensibility was not significantly altered by the 
creation of a surgical AVF at the 6-month follow-up scan 
(2.3±1.2 mmHg−1 vs 2.2±1.2 mmHg−1 [P=0.59]). AA, PDA, 
160
Change in LV mass following AVF creationChange in cardiac output following AVF creation
P<0.0001P<0.0001
Change in LVSV following AVF creationChange in LVESV following AVF creation
P<0.0001P=0.014
Change in LVEDV following AVF creation
P<0.0001



















































































































































Figure 1 Alterations in left ventricular structure and function following AVF-creation.
Abbreviations: aVF, arteriovenous fistula; CMR, cardiovascular magnetic resonance; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; LV, left 
ventricular; NS, nonsignificant; SV, stroke volume.
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DDA, and average aortic distensibility ([AA + PDA + 
DDA]/3) were all numerically, but not statistically signifi-
cantly, lower following AVF-creation.
Prior to AVF-creation, baseline aortic distensibil-
ity decreased progressively from the DDA to the AA, 
consistent with the known regional increase in aortic 
stiffness (reduced aortic compliance) in the more proxi-
mal aortic segments15 (AA 1.41±1.0 mmHg−1 vs PDA 
2.20±1.3 mmHg−1 [P=0.023]; AA 1.41±1.0 mmHg−1 vs DDA 
3.20±2.0 mmHg−1 [P=0.0003]; PDA 2.20±1.3 mmHg−1 vs 
DDA 3.20±2.0 mmHg−1 [P=0.046]). These findings remained 
similar following AVF-creation.
Brachial artery flow-mediated dilatation
A total of 21 subjects completed the full endothelial func-
tion protocol at both scans, with a summary of these find-
ings shown in Figure 3. In these subjects, brachial artery 
endothelium-dependent vasodilatation, as measured by 
flow-mediated dilatation, was markedly reduced at 6-month 
follow-up imaging following AVF-creation (9.0%±9.2% vs 
3.0%±5.7% [P=0.012]). Endothelium-independent vasodi-
latation, in response to glyceryl trinitrate, was unaffected 
by AVF-creation in the subjects evaluated (13.3%±9.1% vs 
12.2%±10.0% [P=0.74]). Notably, in a subpopulation of 
15




































Figure 3 Alterations in peripheral endothelial function following AVF-creation.
Abbreviations: aVF, arteriovenous fistula CMR, cardiovascular magnetic 
resonance; NS, nonsignificant.
80
Change in RVEF following AVF-creation
P=NS
Change in RV stroke volume following AVF-creation
P<0.0001
Change in RVEDV  following AVF-creation
P<0.0001








































































































Figure 2 Alterations in right ventricular structure and function following AVF-creation.
Abbreviations: aVF, arteriovenous fistula; CMR, cardiovascular magnetic resonance; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; 
NS, nonsignificant; RV, right ventricular.
17 subjects where this sequence was performed, there was 
no significant change in baseline brachial artery blood flow 
in the arm contralateral to the AVF (ie, endothelial function 
study arm) (0.054±0.03 L/minute vs 0.055±0.03 L/minute 
[P=0.97]) (Figure 4). The baseline cross-sectional brachial 
artery area was unchanged across the study cohort between 
baseline and follow-up scans (26.5±8 mm2 vs 27.7±7 mm2 
[P=0.31]), negating alterations in baseline flow and brachial 
area characteristics as the cause of these endothelial function 
changes.27
There was no significant correlation between percent 
change in flow-mediated dilatation and percent change 
in AVF flow (r=0.17, P=0.52), percent change in LV 





CO (r=−0.29, P=0.24), or percent change in LVSV 
(r=−0.27, P=0.28).
Brachial artery blood flow – arteriovenous fistula arm
As expected, brachial artery blood flow on the side of the 
AVF was substantially increased 6-months following AVF-
creation (0.057±0.04 L/minute vs 1.158±0.44 L/minute 
[P,0.0001]) (Figure 4). This represents a more than 20-fold 
increase in mean ipsilateral brachial artery blood flow 
6 months following AVF-creation. Notably, there was no 
significant association between increases in the AVF-arm 
brachial artery blood flow and adaptive change in LV CO 
(r=0.09, P=0.71) or LVSV (r=0.13, P=0.59), implicating a 
complex systemic circulatory adaptation to AVF-creation.
Discussion
As demonstrated by this single-arm pilot study, elective 
AVF-creation is associated with substantial alterations in 
cardiac structure and function, necessary to accommodate 
the increase in CO sufficient to service the fistula, whilst 
maintaining a homeostatic systemic supply. These changes 
include biatrial and biventricular dilatation, increased ven-
tricular SV and CO, as well as a clinically significant increase 
in LV mass. Our study has been the first to systemically 
evaluate right and left, ventricular and atrial parameters along 
with measures of vascular function following AVF-creation, 
via gold standard imaging assessment utilizing CMR. In 
our study, this adaptive cardiac remodeling, coupled with 
a .2,000% increase in brachial artery blood flow ipsilateral 
to the newly created AVF, was also associated with a marked 
reduction in remote peripheral endothelial function. Although 
necessary for the provision of HDx, it is striking that an 
elective, purposeful medical intervention could cause such 
widespread maladaptation within the CV system of already 
high-risk individuals.
Previous transthoracic echocardiogram studies have 
 demonstrated the potential for increased LV mass and LV 
dilatation following AVF-creation.2,6 Parfrey et al have 
 previously demonstrated the negative prognostic implications 
of concentric LV hypertrophy, LV dilatation, and LV 
 dysfunction, as measured by echocardiography in ESRF 
patients commencing dialysis.4 Furthermore, London et al 
have previously demonstrated a marked prognostic advantage 
to therapeutic interventions in ESRF that successfully reduce 
LV mass by at least 10%.28 Such measures were associated 
with a 22% reduction in all-cause mortality (relative risk [RR] 
0.78, 95% confidence interval [CI] 0.63–0.92, P=0.0012) and 
a 28% reduction in CV event-free survival (RR 0.72, 95% 
CI 0.51–0.90, P=0.0016).28
In the present study, we demonstrated a 17.2% increase 
in mean LV end-diastolic volume and a 12.7% increase in 
mean LV mass 6 months following AVF-creation. Although 
beyond the scope of this observational study, such cardiac 
adaptations may thus be postulated to impact deleteriously 
on CV morbidity and mortality. Furthermore, recognition 
of the impact of a 25% increase in mean CO at 6 months 
following AVF-creation may be an important factor in the 
clinical management of predialysis patients, despite this 
being rarely reported using conventional cardiac imaging 
modalities.
Likewise, RV structure and function have historically 
been neglected in the evaluation of cardiac structure and 
function in this cohort. Due to its unusual shape and ante-
rior  location, transthoracic echocardiography provides 
only a limited evaluation of RV size and systolic function. 
 Utilizing CMR, we demonstrated substantial alterations 
in RV structure and function following AVF-creation. 


































Figure 4 Alteration in CMR-assessed brachial artery blood-flow, ipsilateral and 
contralateral to the newly created arteriovenous fistula.
Abbreviations: aVF, arteriovenous fistula CMR, cardiovascular magnetic 
resonance; NS, nonsignificant.
Table 2 summary of changes in cardiac structure and function 
following fistula-creation





LV end-systolic  
size (ml)
43±16 52±24 (up 21%) P=0.014
LV end-diastolic  
size (ml)
149±31 175±43 ml (up 17%) P,0.0001
lVeF (%) 72±7 71±9 P=0.60
lVsV (ml) 107±24 124±29 (up 16%) P,0.0001
lV cO (l/min) 7.5±1.5 9.4±2.2 (up 25%) P,0.0001
lVM (g) 132±32 149±35 (up 13%) P,0.0001
RV end-systolic  
size (ml)
49±14 56±18 (up 15%) P=0.0014
RV end-diastolic  
size (ml)
142±32 167±42 (up 18%) P,0.0001
RVeF (%) 66±5 67±6 P=0.45
RVsV (ml) 93±24 112±27 (up 20%) P,0.0001
la (cm2) 27±6 30±6 (up 11%) P=0.0003
Ra (cm2) 23±6 25±6 (up 9%) P=0.0046
Abbreviations: cO, cardiac output; eF, ejection fraction; la, left atrium; lV, left 
ventricular; M, mass; Ra, right atrium; RV, right ventricular; sV, stroke volume.




Cardiovascular adaptations to AV fistula-creation
Although intuitive, such f indings are important to 
appreciate, given the known association of AVF-creation 
and the development of clinically significant pulmonary 
hypertension in ESRF patients. The need for substantial 
increases in pulmonary blood flow related to increased 
CO, coupled with demonstrable increases in LV mass and 
left atrial dilatation, provides a mechanistic cardiac con-
tribution to previous observations of elevated pulmonary 
arterial pressure in the ESRF context.29 Furthermore, it 
is conceivable that AVF-creation may be associated with 
endothelial dysfunction in the pulmonary vascular bed, 
as seen peripherally in our study. The combination of 
alterations in cardiac structure and function associated with 
AVF-creation demonstrated in this study and the possible 
contribution of pulmonary vascular endothelial dysfunc-
tion could contribute to the increase in pulmonary arterial 
pressure in ESRF, with resultant clinical implications. The 
role of subclinical RV remodeling and dysfunction in the 
exercise intolerance of ESRF remains to be determined, 
but the results from this study provide an important link 
in this line of enquiry.
Left atrial size is more commonly increased in ESRF 
in comparison with the general community.30 Left atrial 
 dilatation has previously been identified as an independent 
risk factor for the development of atrial fibrillation in ESRF 
and may contribute to the poor CV prognosis of patients 
with CKD.31,32 Furthermore, whether through the predispo-
sition to AF or as a marker of chronic LV diastolic impair-
ment, recent evidence confirms an association between LA 
 dilatation and increased mortality in ESRF patients with LV 
hypertrophy.32–34 Our study would support the conclusion that 
changes in atrial dimension following AVF-creation may 
play a significant role in the promotion of atrial arrhythmia 
within the ESRF milieu.
Endothelial dysfunction is known to be a critical pre-
condition to the development of atherosclerosis and subse-
quent CV sequelae.35 CKD provides a particularly complex 
precipitant for endothelial dysfunction, resulting from 
multiple circulating factors injurious to the endothelium and 
promotional of the necessary proinflammatory setting for 
endothelial dysfunction and accelerated atherosclerosis.36 
Notably, impairment in forearm flow-mediated dilatation 
has been shown to be associated with an increase in all-cause 
mortality in ESRF37 but has been shown to improve following 
transplantation, providing a valuable, modifiable marker of 
vascular structure and function in response to therapeutic 
interventions in CKD.
In this study, we found a clinically significant reduc-
tion in brachial artery endothelial function 6 months 
following AVF-creation. Such a finding strongly implicates 
a  mechanistic trigger to remote endothelial dysfunction from 
the increased blood flow and vascular shear stress in the AVF 
arm, as well as that induced by the compensatory increase 
in systemic CO required to service the fistula. Furthermore, 
such findings occurred in the absence of detectable changes 
in baseline brachial artery blood flow or cross-sectional area 
in the studied arm. Such findings implicate AVF-creation in 
the promotion of the complex proatherogenic milieu of pro-
gressive CKD and ESRF, and such conduits may contribute 
significantly to the development of accelerated cardiovascular 
disease associated with this condition.
No significant alteration was seen in aortic distensi-
bility at 6 months following AVF-creation, although a 
consistent numerical fall in distensibility was noted at 
each of the aortic levels assessed. Such a finding may of 
course be a chance observation but provides substrate 
for the  hypothesis that 6 months is too short a follow-up 
period to identify chronic alterations in central vascular 
stiffness in response to AVF-creation in the context of 
chronic uremia.
Although similarities exist between our study design 
and that of other published studies evaluating the cardiac 
effects of AVF-creation,2,6 the most significant limitation 
of the current study is the absence of a control group. 
While supply of a control cohort in such a study, clinically 
requiring a fistula for dialysis, would raise a number of 
significant ethical issues, confirmation of these findings 
would need to be undertaken in a randomized control trial 
setting. While acknowledging this pilot study is hypothesis-
generating, it could provide data to adequately power a 
randomized control study. Such a study would provide 
mechanistic impetus to undertake a clinical trial to evaluate 
CV outcomes in subjects who had early vs delayed AVF-
creation in ESRF.
Additionally, although values for the majority of clinically 
relevant parameters evaluated remained stable between the 
study investigations, the progressive decline in renal function 
witnessed cannot be excluded as a potential contributor to the 
CV alterations demonstrated. Exploring further mechanistic 
contributors to our findings, ie, measures of oxidative stress 
to explain endothelial function results, would also add to the 
observational findings of the study.
This pilot study suggests that elective AVF-creation in 
predialysis CKD is associated with significant increases in 
left and right atrial and ventricular chamber volumes and 
LV mass, commensurate with the requirement for a 25% 
mean increase in CO. Furthermore, AVF-creation is associ-
ated with deterioration in systemic endothelial function. 





Such  alterations in CV structure and function may contribute 
to the poor health outcomes observed in this cohort.
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